Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX)

Tipranks - Tipranks - Fri Mar 6, 4:06AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elevance Health (ELV – Research Report) and Janux Therapeutics Inc (JANX – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Elevance Health (ELV)

In a report issued on March 3, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health, with a price target of $391.00. The company’s shares closed last Wednesday at $291.45.

According to TipRanks.com, Baxter is a 1-star analyst with an average return of -0.9% and a 45.0% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Molina Healthcare. ;'>

Currently, the analyst consensus on Elevance Health is a Moderate Buy with an average price target of $389.07, a 36.8% upside from current levels. In a report issued on March 3, Barclays also maintained a Buy rating on the stock with a $393.00 price target.

See the top stocks recommended by analysts >>

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).